Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Amgen (AMGN) and Indivior (INDV)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report), Amgen (AMGN – Research Report) and Indivior (INDV – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alnylam Pharma (ALNY)
In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Alnylam Pharma, with a price target of $408.00. The company’s shares closed last Friday at $338.41.
According to TipRanks.com, Ulz is a 3-star analyst with an average return of
Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $480.81, which is a 40.1% upside from current levels. In a report issued on January 20, Wells Fargo also maintained a Hold rating on the stock with a $376.00 price target.
See today’s best-performing stocks on TipRanks >>
Amgen (AMGN)
In a report released today, Matt Phipps from William Blair maintained a Buy rating on Amgen. The company’s shares closed last Friday at $340.72, close to its 52-week high of $346.85.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $353.44, implying a 3.7% upside from current levels. In a report released yesterday, Oppenheimer also upgraded the stock to Buy with a $400.00 price target.
Indivior (INDV)
In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Indivior. The company’s shares closed last Friday at $34.91.
According to TipRanks.com, Knickerbocker is a top 100 analyst with an average return of
Indivior has an analyst consensus of Strong Buy, with a price target consensus of $43.75, a 26.3% upside from current levels. In a report issued on January 20, Northland Securities also maintained a Buy rating on the stock with a $50.00 price target.
